QuidelOrtho (QDEL) Competitors $37.48 -1.10 (-2.85%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends QDEL vs. CLDX, VIVO, NTLA, MYGN, HSKA, MMSI, HAE, ICUI, XRAY, and NEOGShould you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Heska (HSKA), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), DENTSPLY SIRONA (XRAY), and Neogen (NEOG). These companies are all part of the "medical" sector. QuidelOrtho vs. Celldex Therapeutics Meridian Bioscience Intellia Therapeutics Myriad Genetics Heska Merit Medical Systems Haemonetics ICU Medical DENTSPLY SIRONA Neogen QuidelOrtho (NASDAQ:QDEL) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Which has stronger valuation and earnings, QDEL or CLDX? QuidelOrtho has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuidelOrtho$3.00B0.84-$10.10M-$27.90-1.34Celldex Therapeutics$6.88M254.56-$141.43M-$2.57-10.27 Do analysts rate QDEL or CLDX? QuidelOrtho presently has a consensus price target of $58.83, suggesting a potential upside of 56.97%. Celldex Therapeutics has a consensus price target of $62.25, suggesting a potential upside of 135.80%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than QuidelOrtho.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Do insiders and institutionals have more ownership in QDEL or CLDX? 99.0% of QuidelOrtho shares are owned by institutional investors. 1.0% of QuidelOrtho shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor QDEL or CLDX? In the previous week, QuidelOrtho had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for QuidelOrtho and 7 mentions for Celldex Therapeutics. QuidelOrtho's average media sentiment score of 0.91 beat Celldex Therapeutics' score of 0.14 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, QDEL or CLDX? QuidelOrtho has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Is QDEL or CLDX more profitable? QuidelOrtho has a net margin of -66.25% compared to Celldex Therapeutics' net margin of -1,544.32%. QuidelOrtho's return on equity of 4.24% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets QuidelOrtho-66.25% 4.24% 2.17% Celldex Therapeutics -1,544.32%-19.75%-18.86% Does the MarketBeat Community favor QDEL or CLDX? Celldex Therapeutics received 174 more outperform votes than QuidelOrtho when rated by MarketBeat users. Likewise, 75.15% of users gave Celldex Therapeutics an outperform vote while only 67.22% of users gave QuidelOrtho an outperform vote. CompanyUnderperformOutperformQuidelOrthoOutperform Votes44367.22% Underperform Votes21632.78% Celldex TherapeuticsOutperform Votes61775.15% Underperform Votes20424.85% SummaryCelldex Therapeutics beats QuidelOrtho on 10 of the 19 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get QuidelOrtho News Delivered to You Automatically Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QDEL vs. The Competition Export to ExcelMetricQuidelOrthoDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59B$2.20B$5.06B$8.89BDividend YieldN/A0.75%4.97%4.06%P/E Ratio-1.342.6189.0213.30Price / Sales0.8441.431,207.2881.01Price / Cash3.5114.8239.1736.03Price / Book0.793.116.085.74Net Income-$10.10M$29.98M$119.07M$225.93M7 Day Performance-3.80%-1.26%-1.84%-1.32%1 Month Performance-5.92%-9.92%-3.65%0.60%1 Year Performance-45.84%-14.62%31.62%26.23% QuidelOrtho Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QDELQuidelOrtho4.5813 of 5 stars$37.48-2.9%$58.83+57.0%-45.1%$2.59B$3.00B-1.347,100Analyst ForecastGap DownHigh Trading VolumeCLDXCelldex Therapeutics2.8782 of 5 stars$26.40+5.7%$62.25+135.8%-3.0%$1.66B$6.88M-10.27160Analyst ForecastNews CoverageVIVOMeridian Bioscience1.041 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702Analyst ForecastNTLAIntellia Therapeutics4.5389 of 5 stars$13.12-7.1%$54.94+318.7%-56.7%$1.44B$36.28M-2.41600Analyst ForecastAnalyst RevisionMYGNMyriad Genetics4.2579 of 5 stars$15.30+2.0%$27.36+78.8%-15.3%$1.37B$753.20M0.002,700Analyst ForecastHSKAHeskaN/A$119.99flatN/AN/A$1.31B$257.31M-62.17808MMSIMerit Medical Systems4.4368 of 5 stars$104.08-0.6%$103.36-0.7%+44.9%$6.10B$1.26B51.026,950Insider TradePositive NewsHAEHaemonetics4.925 of 5 stars$84.92+0.1%$107.88+27.0%+2.4%$4.26B$1.31B35.243,657ICUIICU Medical4.0342 of 5 stars$167.59-1.2%$173.00+3.2%+94.1%$4.15B$2.26B0.0014,000Analyst UpgradeShort Interest ↓XRAYDENTSPLY SIRONA4.8932 of 5 stars$18.52-1.9%$29.50+59.3%-38.1%$3.75B$3.97B0.0015,000Analyst DowngradeNEOGNeogen2.1536 of 5 stars$14.90-1.3%$17.50+17.4%-8.5%$3.27B$924.22M-135.452,640 Related Companies and Tools Related Companies Celldex Therapeutics Alternatives Meridian Bioscience Alternatives Intellia Therapeutics Alternatives Myriad Genetics Alternatives Heska Alternatives Merit Medical Systems Alternatives Haemonetics Alternatives ICU Medical Alternatives DENTSPLY SIRONA Alternatives Neogen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QDEL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QDEL Stock Alerts